761
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar

, , , , , & show all
Pages 1057-1064 | Received 22 Feb 2019, Accepted 01 Apr 2019, Published online: 19 Apr 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Oliver von Richter, Terry O’Reilly, Davide Guerrieri, Jamie Fan, Constanze Fey, Steven Schussler, Fabricio Furlan & Lena Lemke. (2023) GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar. Expert Opinion on Biological Therapy 23:8, pages 749-758.
Read now

Articles from other publishers (4)

Halimu N. Haliduola, Fausto Berti, Heimo Stroissnig, Eric Guenzi, Hendrik Otto, Abid Sattar & Ulrich Mansmann. (2022) Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study. BMC Medical Research Methodology 22:1.
Crossref
Hong Zhang, Hong Chen, Xiaojiao Li, Min Wu, Xiaoxue Zhu, Cuiyun Li, Jingrui Liu, Haijing Wei, Yue Hu, Jingjing Wang, Yongmin Yang, Xiangyang Zhu & Yanhua Ding. (2021) A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects. Frontiers in Pharmacology 12.
Crossref
Tom W. J. Huizinga, Yoshifumi Torii & Rafael Muniz. (2020) Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatology and Therapy 8:1, pages 41-61.
Crossref
Martin Schiestl, Gopinath Ranganna, Keith Watson, Byoungin Jung, Karsten Roth, Björn Capsius, Michael Trieb, Peter Bias & Julie Maréchal-Jamil. (2020) The Path Towards a Tailored Clinical Biosimilar Development. BioDrugs 34:3, pages 297-306.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.